Asset profile
insulin human · MannKind (MNKD)
- Indication
- diabetes in children and adolescents aged 6 and older
- Also known as
- Afrezza, Afrezza Inhalation Powder
Company
MNKDMannKind
MNKDMannKindMannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address unmet medical needs, incl…
On the calendar
29
May 2026
May 29, 2026
155 days ago
MNKDMannKindTimeline
Newest first.
More from MannKind
Other drugs and candidates from the same company tracked in this sector.